Global Distribution Lacrimedics already distributes its occlusion therapy devices in the United States and over 45 international markets, indicating a ready-made channel network and potential for scaled partnerships or authorized distributors to broaden reach in untapped regions.

Strategic Partnerships Recent distribution partnership with Innovia Medical suggests openness to channel partnerships; sales teams should explore additional distributor alliances in key markets to accelerate penetration and share market risk.

Targeted Therapy Portfolio Focused on Dry Eye Disease diagnosis and treatment with occlusion therapy devices, creating clear cross-sell opportunities for ophthalmology practices, clinics, and eye care centers already serving dry eye patients.

Mid-Sized Growth With 11-50 employees and revenue between 1M and 10M, Lacrimedics sits in a scale-up phase ideal for enterprise-grade partnerships, bundled offerings, and co-marketing programs that leverage agility and nimble decision-making.

Digital and Tech Enablement Adoption of Google Analytics, Google Cloud and modern web technologies indicates a data-informed go-to-market; sales efforts can leverage digital engagement data to identify high-potential clinics and optimize lead routing.